You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,611,456


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,611,456
Title:Progenitor cells from wharton\'S jelly of human umbilical cord
Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC-/- progenitor cells, and is useful to grow and repair human tissues including bone.
Inventor(s): Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA)
Assignee: Tissue Regeneration Therapeutics Inc. (Toronto, CA)
Application Number:14/884,339
Patent Claims:1. A Wharton's jelly extract, wherein the extract comprises: (i) a cell population, wherein the cell population comprises human progenitor cells having MHC double negative phenotype; (ii) a structural matrix from human umbilical cord perivascular tissue; and (iii) an exogenous enzyme in an amount sufficient to release the cell population from collagen matrix of the Wharton's jelly, wherein the exogenous enzyme is in contact with the structural matrix, and wherein the extract is essentially free from cells of umbilical cord blood.

2. The Wharton's jelly extract of claim 1, wherein the extract is obtained by subjecting umbilical cord vasculature bearing proximal Wharton's jelly to enzymatic digestion in a suitable cell extraction medium.

3. The Wharton's jelly extract of claim 2, wherein the enzymatic digestion results in the release of cells from the collagen matrix of the Wharton's jelly.

4. A Wharton's jelly extract according to claim 3, in which the extraction is performed at 37.degree. C. in phosphate buffered saline and 0.5-10.0 mg/mL collagenase for a period of 1 to 24 hours.

5. The Wharton's jelly extract of claim 1, wherein the extract comprises human umbilical cord perivascular cells having a CD45-phenotype.

6. The Wharton's jelly extract of claim 1, wherein the extract is obtained by mechanical separation.

7. The Wharton's jelly extract of claim 1, wherein the extract obtained is minimally manipulated.

8. The Wharton's jelly extract of claim 1, wherein the exogenous enzyme is collagenase.

9. The Wharton's jelly extract of claim 1, wherein the extract is present in a cryopreserved state.

10. The Wharton's jelly extract of claim 1, wherein the extract is essentially free from cells derived from the vascular structure of the human umbilical cord.

11. The Wharton's jelly extract of claim 1, wherein the extract is enriched for progenitor cells having an MHC double negative phenotype.

12. The Wharton's jelly extract of claim 11, wherein at least 50% of the cells in the extract have an MHC double negative phenotype.

13. The Wharton's jelly extract of claim 12, wherein at least 80% of the cells in the extract have an MHC double negative phenotype.

14. The Wharton's jelly extract of claim 13, wherein at least 90% of the cells in the extract have an MHC double negative phenotype.

15. The Wharton's jelly extract of claim 1, wherein the extract exhibits a disrupted extracellular matrix architecture.

16. The Wharton's jelly extract of claim 1, wherein the extract comprises a carrier.

17. The Wharton's jelly extract of claim 1, wherein the cell population comprises cells further characterized by expression of one or more of the following markers: CD34-, SH2+, SH3+, Thy1+, alpha-actin+, desmin+, and vimentin+.

18. The Wharton's jelly extract of claim 1, wherein the progenitor cells are osteoprogenitor cells, chondrogenic progenitor cells, adipogenic progenitor cells, or myogenic progenitor cells.

19. The Wharton's jelly extract of claim 1, wherein the progenitor cells are capable of differentiating into bone-, fat-, cartilage-, tendon-, or muscle-producing cells.

20. The Wharton's jelly extract of claim 1, wherein the cell population is obtainable from perivascular region of at least one human umbilical cord blood vessel.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.